AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Inclusion Criteria

• •Inclusion Hematologic Malignances Arm
• •Patients must have CLL, prolymphocytic leukemia, or lymphoma (Hodgkins or Non-Hodgkins) as defined by 2008 WHO criteria or multiple myeloma as defined by IMWG criteria
• •Patients must have received at least one prior antineoplastic therapy, must have progressed after at least 1 prior therapy, and for whom no standard therapy is available or whom decline such options; prior autologous and/or allogeneic transplant is permitted
• •Prior biologic therapy or prior radiation is permitted; however, at least 28 days must have elapsed since the completion of prior therapy and patients must have recovered from all therapy-associated toxicities to no greater than grade 1 at the time of registration
• •Patients with symptomatic disease may receive palliative corticosteroids up to 1 week before initiating therapy
• •Patients must be off any prior chemotherapy for at least 28 days or 3 half lives, whichever is longer, and all therapy-related toxicity must have resolved to grade 1 or less
• •ANC \>= 1000/uL
• •Total bilirubin \< 1.5 mg/dL
• •Serum creatinine =\< 1.5x institutional upper limit of normal or estimated creatinine clearance \>= 50 ml/min by MDRD (original or abbreviated), or measured creatinine clearance \>= 50 mL/min
• •ECOG/WHO performance score of 0-1
• •Patients must be able to swallow capsules
• •Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial
• •Women with potential for child bearing must have a negative pregnancy test at screening; both men and women are required to use appropriate contraception during study
• •Platelet count \>= 50,000/uL
• •AST and ALT =\< 5x the institutional upper limit of normal Inclusion Solid Tumors Arm
• •Histologically or cytologically confirmed advanced or recurrent solid tumor malignancy.
• •Chemotherapy: up to three prior cytotoxic chemotherapy treatments.
• •Radiation Therapy: prior radiation therapy allowed.
• •Surgery: Prior curative and palliative intent surgery is allowed.
• •Age ≥ 18 years
• •ECOG performance status 0-1
• •Life expectancy of greater than 12 weeks.
• •Patients must have normal organ and marrow function as defined below:
• •Leukocytes ≥ 3,000/mcL
• •Absolute neutrophil count ≥ 1,500/mcL
• •Platelets ≥ 100,000/mcL
• •Total bilirubin \< 1.5 mg/dL
• •AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal (ULN); ≤ 5 x ULN in presence of liver metastasis
• •Creatinine ≤ 1.5 x ULN OR Creatinine clearance ≥ 50 mL/min by MDRD (original or abbreviated), or measured creatinine clearance ≥ 50 ml/min
• •Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial
• •Women with potential for child bearing must have a negative pregnancy test at screening; both men and women are required to use appropriate contraception during study
• •Exclusion Hematologic Malignances Arm
• •Pregnant women are excluded from this study
• •Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug
• •Breastfeeding should be discontinued if the mother is treated with AR-42